Impact of the NO-donor Pentaerythrithyltetrantrate on Perinatal Outcome in High-risk Pregnancies - Full Text View

Purpose

Pregnancies resulting in IUGR and also in preeclampsia are strongly associated with typical underlying placental pathology revealing small placentas and maldevelopment of the decidual blood vessels, suggesting under-perfusion from the maternal circulation. Since nitric oxide (NO) donors can improve decreased uteroplacental perfusion without any negative effects on fetal circulation, these may prevent negative pregnancy outcomes in patients at risk.

The aim of this study is to evaluate the effectiveness of the long-lasting NO donor pentarythrithyltetranitrate (PETN) to reduce the likelihood of adverse pregnancy outcomes (intrauterine growth retardation / IUGR, perinatal death, placental abruption, and preterm delivery) in women recognized to be at risk for this outcome by abnormal uterine flow in mid gestation.

Condition	Intervention	Phase
High Risk Pregnancy	Drug: PETN Drug: Placebo control	Phase 1 Phase 2


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Prevention
Official Title:	Impact of the NO-donor Pentaerythrithyltetrantrate on Perinatal Outcome in High-risk Pregnancies: a Prospective Randomized Pilot Study

Further study details as provided by University of Jena:

Primary Outcome Measures:

Occurrence of perinatal death and/or IUGR defined as birth weight below the 10th percentile [ Time Frame: 19 -40 weeks of gestation ]

Secondary Outcome Measures:

Development of IUGR and severe IUGR defined as birth weight below the 5th percentile [ Time Frame: 19-40 weeks of gestation ]
Preterm birth before completed 37 weeks of gestation and very early preterm birth before completed 32 weeks of gestation [ Time Frame: 19 - 32 weeks of gestation ]
Development of preeclampsia [ Time Frame: 19 - 40 weeks of gestation ]
Any form of placental abruption [ Time Frame: 19 - 40 weeks of gestation ]


Enrollment:	111
Study Start Date:	April 2002
Primary Completion Date:	January 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Placebo Comparator: Placebo	Drug: Placebo control orally, twice daily
Experimental: PETN Pentalong, Actavis Germay: 80 mg twice a day	Drug: PETN Pentaerythrithyltetranitrate: 80 mg orally twice a day Other Name: Pentalong®, , Actavis Germany, Langenfeld, Germany

Eligibility


Ages Eligible for Study:	18 Years to 50 Years (Adult)
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

pregnant women 190 to 236 weeks of gestation
abnormal uterine Doppler as defined by bilateral notching, unilateral notching and increased impedance with mean resistance index (RI) > 0.65 or with mean RI > 0.7 without notching at time of enrollement
informed consent

Exclusion Criteria:

multiple gestation
documented chromosomal or major fetal abnormalities
rupture of membranes and/or clinical chorioamnionitis at time of enrolment
maternal disease defined as contraindication for intake of PETN

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01355822

Locations


Germany
University Hospital Jena, Department of Obstetrics
Jena, Thüringen, Germany, 07743

Sponsors and Collaborators

University of Jena

More Information


Responsible Party:	Prof. Dr. Ekkehard Schleußner, University Hospital Jena, Deartmet og Obstetrics
ClinicalTrials.gov Identifier:	NCT01355822 History of Changes
Other Study ID Numbers:	PETN_ESTG
Study First Received:	May 16, 2011
Last Updated:	May 26, 2011

Keywords provided by University of Jena:


abortion perinatal death IUGR	preterm birth placental abruption preeclampsia

ClinicalTrials.gov processed this record on July 19, 2017